PMID: 7940683Sep 27, 1994Paper

Impact of de novo membranous glomerulonephritis on the clinical course after kidney transplantation

Transplantation
A SchwarzF Keller

Abstract

Besides rejection-induced transplant glomerulopathy de novo membranous glomerulonephritis (MGN) is the most frequent cause of nephrotic syndrome after renal transplantation. We evaluated 1029 renal transplantations (271 without and 758 with cyclosporine treatment), performed on 848 patients between 1970 and 1992, which resulted in 872 functioning grafts. De novo MGN was seen in 30 biopsy specimens from 21 patients (about 2%), of whom 10 had received immunosuppressive treatment without and 11 with cyclosporine. Taking into account the longer periods of observation of patients without compared with those with cyclosporine treatment (88 +/- 60 vs. 41 +/- 31 mo., respectively, P = 0.001), the two treatment groups did not differ significantly in prevalence of de novo MGN (4.0% vs. 1.5%). De novo MGN was diagnosed by biopsy 62.7 +/- 44.4 mo. after transplantation; its incidence increased significantly with time (from 0% to 5.3% over 8 years; 95% confidential interval: 1.7-8%). Proteinuria (mean, 3.2 +/- 2.9 g/L) was first observed 47.5 +/- 51.3 mo. after transplantation. Thirteen of the 21 patients (62%) were nephrotic (proteinuria, over 1.5 g/L). Steroid pulses were given to 12 patients with de novo MGN and high proteinuria, which d...Continue Reading

Citations

Nov 13, 2009·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Shina Menon, Rudolph P Valentini
Apr 18, 2002·Transplantation Proceedings·F Teixeira e CostaM J Galvão
Jun 27, 2003·Transplantation Proceedings·M CampiseClaudio Ponticelli
Jun 17, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·J Floege
Dec 3, 2004·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Claudio Ponticelli
Dec 20, 2007·Transplantation Proceedings·M BohatyrewiczK Ciechanowski
May 1, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·T S DabadeFernando G Cosio
Aug 11, 2011·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·H DebiecP Ronco
Jul 30, 2011·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·L K HendersonJ R Chapman
Mar 20, 2010·Clinical Transplantation·Kazuho HondaYutaka Yamaguchi
Oct 26, 2005·Fetal and Pediatric Pathology·N J Sebire, D Bockenhauer
Oct 12, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Cathryn J Byrne-DuganIbrahim Batal
Sep 1, 1996·Kidney International·R B Colvin
Sep 21, 2016·Clinical Transplantation·Edward J Filippone, John L Farber

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.